<?xml version='1.0' encoding='utf-8'?>
<document id="25297453"><sentence text="Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3."><entity charOffset="92-103" id="DDI-PubMed.25297453.s1.e0" text="ginsenoside" /></sentence><sentence text="Ginsenosides are bioactive saponins derived from Panax notoginseng roots (Sanqi) and ginseng"><entity charOffset="0-12" id="DDI-PubMed.25297453.s2.e0" text="Ginsenosides" /><entity charOffset="27-35" id="DDI-PubMed.25297453.s2.e1" text="saponins" /><pair ddi="false" e1="DDI-PubMed.25297453.s2.e0" e2="DDI-PubMed.25297453.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s2.e0" e2="DDI-PubMed.25297453.s2.e1" /></sentence><sentence text=" Here, the molecular mechanisms governing differential pharmacokinetics of 20(S)-protopanaxatriol-type ginsenoside Rg1 , ginsenoside Re and notoginsenoside R1 and 20(S)-protopanaxadiol-type ginsenosides Rb1, Rc and Rd were elucidated"><entity charOffset="75-97" id="DDI-PubMed.25297453.s3.e0" text="20(S)-protopanaxatriol" /><entity charOffset="103-118" id="DDI-PubMed.25297453.s3.e1" text="ginsenoside Rg1" /><entity charOffset="121-135" id="DDI-PubMed.25297453.s3.e2" text="ginsenoside Re" /><entity charOffset="140-155" id="DDI-PubMed.25297453.s3.e3" text="notoginsenoside" /><entity charOffset="163-184" id="DDI-PubMed.25297453.s3.e4" text="20(S)-protopanaxadiol" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e0" e2="DDI-PubMed.25297453.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e0" e2="DDI-PubMed.25297453.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e0" e2="DDI-PubMed.25297453.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e0" e2="DDI-PubMed.25297453.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e0" e2="DDI-PubMed.25297453.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e1" e2="DDI-PubMed.25297453.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e1" e2="DDI-PubMed.25297453.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e1" e2="DDI-PubMed.25297453.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e1" e2="DDI-PubMed.25297453.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e2" e2="DDI-PubMed.25297453.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e2" e2="DDI-PubMed.25297453.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e2" e2="DDI-PubMed.25297453.s3.e4" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e3" e2="DDI-PubMed.25297453.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25297453.s3.e3" e2="DDI-PubMed.25297453.s3.e4" /></sentence><sentence text="" /><sentence text="Interactions of ginsenosides with human and rat hepatobiliary transporters were characterized at the cellular and vesicular levels" /><sentence text=" A rifampin-based inhibition study in rats evaluated the in vivo role of organic anion-transporting polypeptide (Oatp)1b2"><entity charOffset="3-11" id="DDI-PubMed.25297453.s6.e0" text="rifampin" /></sentence><sentence text=" Plasma protein binding was assessed by equilibrium dialysis" /><sentence text=" Drug-drug interaction indices were calculated to estimate potential for clinically relevant ginsenoside-mediated interactions due to inhibition of human OATP1Bs"><entity charOffset="93-104" id="DDI-PubMed.25297453.s8.e0" text="ginsenoside" /></sentence><sentence text="" /><sentence text="All the ginsenosides were bound to human OATP1B3 and rat Oatp1b2 but only the 20(S)-protopanaxatriol-type ginsenosides were transported"><entity charOffset="78-100" id="DDI-PubMed.25297453.s10.e0" text="20(S)-protopanaxatriol" /><entity charOffset="106-118" id="DDI-PubMed.25297453.s10.e1" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.25297453.s10.e0" e2="DDI-PubMed.25297453.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s10.e0" e2="DDI-PubMed.25297453.s10.e1" /></sentence><sentence text=" Human multidrug resistance-associated protein (MRP)2/breast cancer resistance protein (BCRP)/bile salt export pump (BSEP)/multidrug resistance protein-1 and rat Mrp2/Bcrp/Bsep also mediated the transport of the 20(S)-protopanaxatriol-type ginsenosides"><entity charOffset="212-234" id="DDI-PubMed.25297453.s11.e0" text="20(S)-protopanaxatriol" /><entity charOffset="240-252" id="DDI-PubMed.25297453.s11.e1" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.25297453.s11.e0" e2="DDI-PubMed.25297453.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s11.e0" e2="DDI-PubMed.25297453.s11.e1" /></sentence><sentence text=" Glomerular-filtration-based renal excretion of the 20(S)-protopanaxatriol-type ginsenosides was greater than that of the 20(S)-protopanaxadiol-type counterparts due to differences in plasma protein binding"><entity charOffset="52-74" id="DDI-PubMed.25297453.s12.e0" text="20(S)-protopanaxatriol" /><entity charOffset="80-92" id="DDI-PubMed.25297453.s12.e1" text="ginsenosides" /><entity charOffset="122-143" id="DDI-PubMed.25297453.s12.e2" text="20(S)-protopanaxadiol" /><pair ddi="false" e1="DDI-PubMed.25297453.s12.e0" e2="DDI-PubMed.25297453.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s12.e0" e2="DDI-PubMed.25297453.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s12.e0" e2="DDI-PubMed.25297453.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25297453.s12.e1" e2="DDI-PubMed.25297453.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s12.e1" e2="DDI-PubMed.25297453.s12.e2" /></sentence><sentence text=" Rifampin-impaired hepatobiliary excretion of the 20(S)-protopanaxatriol-type ginsenosides was effectively compensated by the renal excretion in rats"><entity charOffset="1-9" id="DDI-PubMed.25297453.s13.e0" text="Rifampin" /><entity charOffset="50-72" id="DDI-PubMed.25297453.s13.e1" text="20(S)-protopanaxatriol" /><entity charOffset="78-90" id="DDI-PubMed.25297453.s13.e2" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.25297453.s13.e0" e2="DDI-PubMed.25297453.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s13.e0" e2="DDI-PubMed.25297453.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s13.e0" e2="DDI-PubMed.25297453.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25297453.s13.e1" e2="DDI-PubMed.25297453.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25297453.s13.e1" e2="DDI-PubMed.25297453.s13.e2" /></sentence><sentence text=" The 20(S)-protopanaxadiol-type ginsenosides were potent inhibitors of OATP1B3"><entity charOffset="5-26" id="DDI-PubMed.25297453.s14.e0" text="20(S)-protopanaxadiol" /><entity charOffset="32-44" id="DDI-PubMed.25297453.s14.e1" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.25297453.s14.e0" e2="DDI-PubMed.25297453.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s14.e0" e2="DDI-PubMed.25297453.s14.e1" /></sentence><sentence text="" /><sentence text="Differences in hepatobiliary and in renal excretory clearances caused markedly different systemic exposure and different elimination kinetics between the two types of ginsenosides"><entity charOffset="167-179" id="DDI-PubMed.25297453.s16.e0" text="ginsenosides" /></sentence><sentence text=" Caution should be exercised with the long-circulating 20(S)-protopanaxadiol-type ginsenosides as they could induce hepatobiliary herb-drug interactions, particularly when patients receive long-term therapies with high-dose i"><entity charOffset="55-76" id="DDI-PubMed.25297453.s17.e0" text="20(S)-protopanaxadiol" /><entity charOffset="82-94" id="DDI-PubMed.25297453.s17.e1" text="ginsenosides" /><pair ddi="false" e1="DDI-PubMed.25297453.s17.e0" e2="DDI-PubMed.25297453.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25297453.s17.e0" e2="DDI-PubMed.25297453.s17.e1" /></sentence><sentence text="v" /><sentence text=" Sanqi or ginseng extracts" /><sentence text="" /></document>